Zevra Therapeutics Inc. (ZVRA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zevra Therapeutics Inc. (ZVRA) has a cash flow conversion efficiency ratio of 0.035x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($4.71 Million) by net assets ($133.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Zevra Therapeutics Inc. for the company's overall valuation and market capitalisation.
Zevra Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Zevra Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Zevra Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zevra Therapeutics Inc. ranked by their cash flow conversion efficiency. Explore Zevra Therapeutics Inc. (ZVRA) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SAMT Co. Ltd
KQ:031330
|
0.146x |
|
Farmacias Benavides S.A.B. de C.V.
MX:BEVIDESB
|
0.822x |
|
COOR Service Management AB
ST:COOR
|
0.050x |
|
Guangzhou Amsky Technology Co Ltd
SHE:300521
|
-0.033x |
|
Gruvaktiebolaget Viscaria
ST:VISC
|
-0.018x |
|
Shenzhen Haoningda Meters Co Ltd
SHE:002356
|
-0.013x |
|
Hubei Sanxia New Building Materials Co Ltd
SHG:600293
|
-0.006x |
|
Brisa Bridgestone Sabanci Lastik Sanayi ve Ticaret AS
IS:BRISA
|
0.058x |
Annual Cash Flow Conversion Efficiency for Zevra Therapeutics Inc. (2012–2024)
The table below shows the annual cash flow conversion efficiency of Zevra Therapeutics Inc. from 2012 to 2024. View Zevra Therapeutics Inc. stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $39.67 Million | $-69.67 Million | -1.756x | -223.99% |
| 2023-12-31 | $61.86 Million | $-33.53 Million | -0.542x | -117.56% |
| 2022-12-31 | $75.12 Million | $-18.72 Million | -0.249x | -403.41% |
| 2021-12-31 | $127.12 Million | $10.44 Million | 0.082x | +181.27% |
| 2020-12-31 | $-66.41 Million | $-1.94 Million | 0.029x | -90.84% |
| 2019-12-31 | $-74.46 Million | $-23.74 Million | 0.319x | -60.85% |
| 2018-12-31 | $-66.57 Million | $-54.20 Million | 0.814x | +41.49% |
| 2017-12-31 | $-57.52 Million | $-33.10 Million | 0.575x | -63.86% |
| 2016-12-31 | $-18.70 Million | $-29.77 Million | 1.592x | -20.48% |
| 2015-12-31 | $-10.12 Million | $-20.27 Million | 2.003x | +231.64% |
| 2014-12-31 | $-24.30 Million | $-14.67 Million | 0.604x | +238.65% |
| 2013-12-31 | $-24.27 Million | $-4.33 Million | 0.178x | -97.48% |
| 2012-12-31 | $-627.22K | $-4.43 Million | 7.070x | -- |
About Zevra Therapeutics Inc.
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under P… Read more